Scientists Identify Key Proteins Driving mRNA Vaccine-Related Myocarditis,Find Potential Soybean-Derived Solution
A new study pinpoints two proteins,CXCL10 adn IFN-gamma,as major contributors to myocarditis following mRNA vaccination,while also suggesting the dietary supplement genistein – found in soybeans – may offer a preventative approach. The research, published in Sci Transl Med in February 2025, sheds light on the inflammatory processes triggered by vaccination and offers a potential avenue for mitigating cardiac risks.
Researchers discovered that these two proteins operate in tandem, acting as “major drivers” of the heart inflammation. CXCL10 and IFN-gamma are both classified as cytokines, signaling molecules used by immune cells to communicate with each other.
To understand this communication, scientists generated human macrophages – critical first responders of the immune system – and exposed them to mRNA vaccines in vitro. The macrophages responded by releasing significant amounts of CXCL10, mirroring responses observed in vaccinated individuals. Further experiments revealed that adding T cells – immune cells that identify and attack pathogens – to the mix, or even exposing them to fluid from vaccinated individuals, prompted the release of IFN-gamma. The study confirmed that CXCL10 and IFN-gamma directly contribute to cardiac injury in the animal model, and that blocking them preserved the immune response while reducing heart damage.
To further investigate the mechanisms at play, the researchers utilized a sophisticated technique to create “cardiac spheroids” – three-dimensional structures mimicking the heart’s rhythmic contractions. Treating these spheroids with CXCL10 and IFN-gamma, derived from vaccine-stimulated immune cells, led to signs of cardiac stress. However, this stress was alleviated when cytokine inhibitors were introduced. The spheroids’ ability to contract and maintain a healthy beating rate was also impaired by the cytokines, but partially restored with the inhibitors.
Seeking a preventative measure, researchers turned to genistein, a compound found in soybeans with known anti-inflammatory properties. A 2022 study published in Cell had already identified genistein’s ability to counter inflammation and protect against vascular and heart tissue damage. “Genistein is only weakly absorbed when taken orally,” one researcher noted, adding, “Nobody ever overdosed on tofu.”
Experiments pre-treating cells, cardiac spheroids, and mice with genistein demonstrated its protective effects, preventing much of the damage caused by mRNA vaccines or the CXCL10/IFN-gamma combination. The genistein used in the study was a highly purified and concentrated form.
The researchers also suggest that the inflammatory response triggered by mRNA vaccines may not be limited to the heart. “It’s reasonable to believe that the mRNA-vaccine-induced inflammatory response may extend to other organs,” one researcher stated, citing evidence of similar effects in the lungs, liver, and kidneys. Genistein, they hypothesize, could possibly reverse these changes as well.
The study emphasizes that elevated cytokine signaling is a natural part of the immune response to mRNA vaccines, essential for fighting viruses. However, excessive amounts can become toxic, leading to myocarditis-like symptoms and heart muscle degradation. This risk, researchers believe, isn’t unique to COVID-19 vaccines. “Other vaccines can cause myocarditis and inflammatory problems, but the symptoms tend to be more diffuse,” one researcher explained. The heightened scrutiny surrounding mRNA-based COVID-19 vaccines means that cardiac symptoms are more likely to be investigated and diagnosed, unlike those following other vaccinations.
This research underscores the complex interplay between immune response and potential adverse effects, offering a crucial step toward understanding and mitigating vaccine-related risks.
Reference: Cao X, Manhas A, Chen YI, et al.Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination.sci Transl Med. 2025;17(828):eadq0143. doi: 10.1126/scitranslmed.adq0143.
